FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286268296> ?p ?o ?g. }

• W4286268296 endingPage "399" @default.
• W4286268296 startingPage "387" @default.
• W4286268296 abstract "Alphavirus vectors based on self-amplifying RNA (saRNA) generate high and transient levels of transgene expression and induce innate immune responses, making them an interesting tool for antitumor therapy. These vectors are usually delivered as viral particles, but it is also possible to administer them as RNA. We evaluated this possibility by in vivo electroporation of Semliki Forest virus (SFV) saRNA for local treatment of murine colorectal MC38 subcutaneous tumors. Optimization of saRNA electroporation conditions in tumors was performed using an SFV vector coding for luciferase. Then we evaluated the therapeutic potential of this approach using an SFV saRNA coding for interleukin-12 (SFV-IL-12), a proinflammatory cytokine with potent antitumor effects. Delivery of SFV-IL-12 saRNA by electroporation led to improvement in tumor control and higher survival compared with mice treated with electroporation or with SFV-IL-12 saRNA alone. The antitumor efficacy of SFV-IL-12 saRNA electroporation increased by combination with systemic PD-1 blockade. This therapy, which was also validated in a hepatocellular carcinoma tumor model, suggests that local delivery of saRNA by electroporation could be an attractive strategy for cancer immunotherapy. This approach could have easy translation to the clinical practice, especially for percutaneously accessible tumors. Alphavirus vectors based on self-amplifying RNA (saRNA) generate high and transient levels of transgene expression and induce innate immune responses, making them an interesting tool for antitumor therapy. These vectors are usually delivered as viral particles, but it is also possible to administer them as RNA. We evaluated this possibility by in vivo electroporation of Semliki Forest virus (SFV) saRNA for local treatment of murine colorectal MC38 subcutaneous tumors. Optimization of saRNA electroporation conditions in tumors was performed using an SFV vector coding for luciferase. Then we evaluated the therapeutic potential of this approach using an SFV saRNA coding for interleukin-12 (SFV-IL-12), a proinflammatory cytokine with potent antitumor effects. Delivery of SFV-IL-12 saRNA by electroporation led to improvement in tumor control and higher survival compared with mice treated with electroporation or with SFV-IL-12 saRNA alone. The antitumor efficacy of SFV-IL-12 saRNA electroporation increased by combination with systemic PD-1 blockade. This therapy, which was also validated in a hepatocellular carcinoma tumor model, suggests that local delivery of saRNA by electroporation could be an attractive strategy for cancer immunotherapy. This approach could have easy translation to the clinical practice, especially for percutaneously accessible tumors." @default.
• W4286268296 created "2022-07-21" @default.
• W4286268296 creator A5008117181 @default.
• W4286268296 creator A5015790502 @default.
• W4286268296 creator A5022551544 @default.
• W4286268296 creator A5055309200 @default.
• W4286268296 creator A5078526423 @default.
• W4286268296 creator A5087768213 @default.
• W4286268296 date "2022-09-01" @default.
• W4286268296 modified "2023-10-16" @default.
• W4286268296 title "Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer" @default.
• W4286268296 cites W1159861795 @default.
• W4286268296 cites W1678871737 @default.
• W4286268296 cites W1828970458 @default.
• W4286268296 cites W1963568344 @default.
• W4286268296 cites W1970847065 @default.
• W4286268296 cites W1978180739 @default.
• W4286268296 cites W1984101482 @default.
• W4286268296 cites W1990459596 @default.
• W4286268296 cites W1995004309 @default.
• W4286268296 cites W2009219530 @default.
• W4286268296 cites W2010481103 @default.
• W4286268296 cites W2028936167 @default.
• W4286268296 cites W2047256102 @default.
• W4286268296 cites W2055091294 @default.
• W4286268296 cites W2057294180 @default.
• W4286268296 cites W2066418118 @default.
• W4286268296 cites W206707964 @default.
• W4286268296 cites W2076585749 @default.
• W4286268296 cites W2077962237 @default.
• W4286268296 cites W2092878705 @default.
• W4286268296 cites W2098174187 @default.
• W4286268296 cites W2112242714 @default.
• W4286268296 cites W2114203714 @default.
• W4286268296 cites W2121830723 @default.
• W4286268296 cites W2122105807 @default.
• W4286268296 cites W2128799252 @default.
• W4286268296 cites W2130464657 @default.
• W4286268296 cites W2139871947 @default.
• W4286268296 cites W2143716567 @default.
• W4286268296 cites W2147112708 @default.
• W4286268296 cites W2158817916 @default.
• W4286268296 cites W2162613747 @default.
• W4286268296 cites W2168467781 @default.
• W4286268296 cites W2322861634 @default.
• W4286268296 cites W2326188833 @default.
• W4286268296 cites W2595182131 @default.
• W4286268296 cites W2774013218 @default.
• W4286268296 cites W2901621951 @default.
• W4286268296 cites W2946656616 @default.
• W4286268296 cites W2955806244 @default.
• W4286268296 cites W2966702973 @default.
• W4286268296 cites W2968557592 @default.
• W4286268296 cites W2972065543 @default.
• W4286268296 cites W2973257820 @default.
• W4286268296 cites W2979702545 @default.
• W4286268296 cites W3006298421 @default.
• W4286268296 cites W3007791756 @default.
• W4286268296 cites W3013454916 @default.
• W4286268296 cites W3028523516 @default.
• W4286268296 cites W3031409212 @default.
• W4286268296 cites W3041318796 @default.
• W4286268296 cites W3043351106 @default.
• W4286268296 cites W3083368405 @default.
• W4286268296 cites W3093225819 @default.
• W4286268296 cites W3096324736 @default.
• W4286268296 cites W3112613261 @default.
• W4286268296 cites W3125704052 @default.
• W4286268296 cites W3136399291 @default.
• W4286268296 cites W3142013426 @default.
• W4286268296 cites W3181844424 @default.
• W4286268296 cites W3213011193 @default.
• W4286268296 cites W4241685416 @default.
• W4286268296 doi "https://doi.org/10.1016/j.omtn.2022.07.020" @default.
• W4286268296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36035753" @default.
• W4286268296 hasPublicationYear "2022" @default.
• W4286268296 type Work @default.
• W4286268296 citedByCount "9" @default.
• W4286268296 countsByYear W42862682962023 @default.
• W4286268296 crossrefType "journal-article" @default.
• W4286268296 hasAuthorship W4286268296A5008117181 @default.
• W4286268296 hasAuthorship W4286268296A5015790502 @default.
• W4286268296 hasAuthorship W4286268296A5022551544 @default.
• W4286268296 hasAuthorship W4286268296A5055309200 @default.
• W4286268296 hasAuthorship W4286268296A5078526423 @default.
• W4286268296 hasAuthorship W4286268296A5087768213 @default.
• W4286268296 hasBestOaLocation W42862682962 @default.
• W4286268296 hasConcept C102230213 @default.
• W4286268296 hasConcept C104317684 @default.
• W4286268296 hasConcept C111599444 @default.
• W4286268296 hasConcept C153911025 @default.
• W4286268296 hasConcept C186852380 @default.
• W4286268296 hasConcept C203014093 @default.
• W4286268296 hasConcept C2780963514 @default.
• W4286268296 hasConcept C502942594 @default.
• W4286268296 hasConcept C54009773 @default.
• W4286268296 hasConcept C54355233 @default.
• W4286268296 hasConcept C55493867 @default.

• next